Pharming gives update on outstanding number of shares
Leiden, The Netherlands, June 30, 2009. Biotech company Pharming
Group NV ("Pharming") (NYSE Euronext: PHARM) today provided an update
on its outstanding number of shares following a transaction with YA
Global Master SPV LTD ("YA Global").
Under the Standby Equity Distribution Agreement with YA Global,
Pharming issued 1,158,011 ordinary shares for a cash consideration of
¤ 0.6 million. As a result of the above transactions, Pharming's
total number of outstanding ordinary shares is currently 112,362,987
shares.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment
of genetic disorders, ageing diseases, specialty products for
surgical indications, intermediates for various applications and
nutritional products. Pharming has two products in late stage
development - Rhucin® for Hereditary Angioedema and human Lactoferrin
for use in food products and one product in early stage clinical
development - Prodarsan® for Cockayne Syndrome. The advanced
technologies of the Company include innovative platforms for the
production of protein therapeutics, technology and processes for the
purification and formulation of these products, as well as technology
in the field of DNA repair (via DNage). Additional information is
available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve
known and unknown risks, uncertainties and other factors, which may
cause the actual results, performance or achievements of the Company
to be materially different from the results, performance or
achievements expressed or implied by these forward looking
statements.
Contact:
Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.